(1/545) Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy.

Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors.  (+info)

(2/545) Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart.

Norepinephrine (NE) reuptake function is impaired in heart failure and this may participate in myocyte hyperstimulation by the neurotransmitter. This alteration can be assessed by 123I-metaiodobenzylguanidine (MIBG) scintigraphy. METHODS: To determine whether the impairment of neuronal NE reuptake was reversible after metoprolol therapy, we studied 18 patients (43+/-7 y) with idiopathic dilated cardiomyopathy who were stabilized at least for 3 mo with captopril and diuretics. Patients underwent, before and after 6 mo of therapy with metoprolol, measurements of radionuclide left ventricular ejection fraction (LVEF), maximal oxygen consumption and plasma NE concentration. The cardiac adrenergic innervation function was scintigraphically assessed with MIBG uptake and release measurements on the planar images obtained 20 min and 4 h after tracer injection. To evaluate whether metoprolol had a direct interaction with cardiac MIBG uptake and release, six normal subjects were studied before and after a 1-mo metoprolol intake. RESULTS: In controls, neither cardiac MIBG uptake and release nor circulating NE concentration changed after the 1-mo metoprolol intake. Conversely, after a 6-mo therapy with metoprolol, patients showed increased cardiac MIBG uptake (129%+/-10% versus 138%+/-17%; P = 0.009), unchanged cardiac MIBG release and decreased plasma NE concentration (0.930+/-412 versus 0.721+/-0.370 ng/mL; P = 0.02). In parallel, patients showed improved New York Heart Association class (2.44+/-0.51 versus 2.05+/-0.23; P = 0.004) and increased LVEF (20%+/-8% versus 27%+/-8%; P = 0.0005), whereas maximal oxygen uptake remained unchanged. CONCLUSION: Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation.  (+info)

(3/545) Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

(4/545) Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).

meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg(-1). The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg(-1) for 5 sequential days or of 20 mg kg(-1) for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients.  (+info)

(5/545) Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis.

OBJECTIVES: This prospective study was undertaken to correlate early and late metaiodobenzylguanidine (MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2). BACKGROUND: The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure. Whether it is related to exercise capacity and has better prognostic value than peak VO2 is unknown. METHODS: Ninety-three patients with heart failure (ejection fraction <45%) were studied with planar MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n = 44). Early (20 min) and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined. Prognostic value was assessed by survival curves (Kaplan-Meier method) and uni- and multivariate Cox analyses. RESULTS: Late cardiac MIBG uptake was reduced (131+/-20%, normal values 192+/-42%) and correlated with ejection fraction (r = 0.49), cardiac index (r = 0.40) and pulmonary wedge pressure (r = -0.35). There was a significant correlation between peak VO2 and MIBG uptake (r = 0.41, p < 0.0001). With a mean follow-up of 10+/-8 months, both late MIBG uptake (p = 0.04) and peak VO2 (p < 0.0001) were predictive of death or heart transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG uptake nor WO yielded significant insights beyond those provided by late MIBG uptake. CONCLUSIONS: Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart failure, but peak VO2 remains the most powerful prognostic index.  (+info)

(6/545) Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value.

Myocardial imaging with 123I-metaiodobenzylguanidine (MIBG) was performed on 35 patients with Parkinson's disease and 24 control subjects to evaluate cardiac sympathetic function in patients with Parkinson's disease, verify this phenomenon and examine whether myocardial MIBG uptake and clearance are correlated with the clinical severity of Parkinson's disease. METHODS: We studied 35 patients with Parkinson's disease and 24 control subjects with other central nervous system diseases. The latter group consisted of 12 subjects with other neurodegenerative disorders (4 with spinocerebellar degeneration, 2 with amyotrophic lateral sclerosis, 3 with progressive supranuclear palsy and 3 with corticobasal degeneration and 12 patients with cerebral infarction (CI), 6 with vascular parkinsonism and 6 without it. Early and delayed images of the anterior view were obtained 15 min and 4 h after injection of 123I-MIBG, respectively. MIBG uptake was quantified by calculating a heart-to-mediastinum count (H/M) ratio. RESULTS: The H/M ratio was markedly reduced in the patients with Parkinson's disease (II to V on the Hoehn and Yahr scale) compared with the control subjects. None of the subjects with neurodegenerative diseases showed a marked decrease in myocardial MIBG uptake nor did any subject with CI. CONCLUSION: Our findings indicate that, in Parkinson's disease, a reduction in myocardial MIBG uptake is a very common, specific phenomenon that can be used to detect cardiac autonomic dysfunction to diagnose Parkinson's disease, particularly in patients without typical signs and symptoms.  (+info)

(7/545) Myocardial stunning caused by sympathetic nerve injury after an operation on cervical vertebrae.

In this case, electrocardiographic inverted T waves appeared after cervical laminaplasty and echocardiogram showed temporary wall motion abnormality. Myocardial metaiodobenzylguanidine (MIBG) uptake was obviously reduced in the same area where the wall motion abnormalities appeared in the echocardiogram, although no abnormalities were detected with myocardial thallium scintigraphy and coronary angiography. The myocardial stunning was caused by injury to the sympathetic nerves from a surgical procedure on the cervical vertebrae.  (+info)

(8/545) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

OBJECTIVES: (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson's disease, (2) the usefulness of (123)I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in (123)I-MIBG myocardial scintigraphy, (4) the usefulness of (123)I-MIBG myocardial scintigraphy to differentiate Parkinson's disease from the other neurological diseases mimicking it. METHODS: (123)I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson's disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy. RESULTS: In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson's disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson's disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia. CONCLUSION: (123)I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson's disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson's disease.  (+info)

*  List of MeSH codes (D02)
5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole MeSH D02.640.600.290 --- fanft MeSH D02.640.600.308 --- furagin MeSH ... 3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide MeSH D02.092.146.325 --- p-dimethylaminoazobenzene MeSH ... vitamin k 3 MeSH D02.455.849.291.850 --- taxoids MeSH D02.455.849.291.850.777 --- paclitaxel MeSH D02.455.849.365 --- dolichol ... 3-diketogulonic acid MeSH D02.241.081.844.300 --- glucaric acid MeSH D02.241.081.844.322 --- gluconates MeSH D02.241.081.844. ...
*  Iodine-131
Iodobenzylguanidine. J Nucl Med 25:2-6, 1984 "Medical isotopes the likely cause of radiation in Ottawa waste". CBC News. 4 ... 81 (8): 2930-3. doi:10.1210/jc.81.8.2930. PMID 8768854. Lawrence, J. E.; Lamm, S. H.; Pino, S.; Richman, K.; Braverman, L. E. ( ... The majority of I-131 will be eliminated from the human body in 3-5 days, through natural decay, and through excretion in sweat ... 1 (3): 197-203. doi:10.1023/A:1010031115233. ISSN 1389-9155. PMID 11705004. Frot, Jacques. "THE CAUSES OF THE CHERNOBYL EVENT ...
*  Neuroblastoma
... meta-iodobenzylguanidine), which is taken up by 90 to 95% of all neuroblastomas, often termed "mIBG-avid." The mechanism is ... ISBN 978-3-540-26616-7. Beckwith, J. Bruce; Perrin, Eugene V. (1963). "In Situ Neuroblastomas: a Contribution to the Natural ... Stage 3: Tumor infiltrating across midline with or without regional lymph node involvement; or unilateral tumor with ... The degree of amplification shows a bimodal distribution: either 3- to 10-fold, or 100- to 300-fold. The presence of this ...
*  Nuclear medicine physician
... meta-iodobenzylguanidine (MIBG) imaging for neuroendocrine tumors, heat-damaged red blood cell imaging for identifying ectopic ... 1996 Jul;26(3):191-193. PMID 8829280. PET center of excellence ABNM brochure nuclear medicine technologists American Board of ...
Most recent papers with the keyword iodine uptake | Read by QxMD  Most recent papers with the keyword iodine uptake | Read by QxMD
... have been a promising yet unattainable derivative of radioiodine-labeled meta-iodobenzylguanidine (MIBG), because of the ... Radiolabeled (4-Fluoro-3-iodobenzyl)guanidine improves imaging and targeted radionuclide therapy of norepinephrine transporter- ... Fluorine-18 (18F)/Iodine-131 (131I)-labeled (4-Fluoro-3-iodobenzyl)guanidine (FIBG) ... 3-fluoropropyl)-nortropane (123I-FP-CIT) single photon emission computed tomography and compared with 18 healthy subjects and ...
more infohttps://www.readbyqxmd.com/keyword/61564
Diastolic filling abnormalities during exercise in patients with Heart Failure with a Preserved Ejection Ffraction (HFPEF) as...  Diastolic filling abnormalities during exercise in patients with Heart Failure with a Preserved Ejection Ffraction (HFPEF) as...
Cardiac sympathetic activity can be assessed by 123I-labelled meta-iodobenzylguanidine (MIBG) scintigraphy. Abnormalities of ... 70 Issue 3, p14 Reports on the benefits of extensive patient education and follow-up care to treat congestive heart failure. ...
more infohttp://connection.ebscohost.com/c/abstracts/36113840/diastolic-filling-abnormalities-during-exercise-patients-heart-failure-preserved-ejection-ffraction-hfpef-as-measured-by-radionuclide-ventriculography
Iodine-123 Metaiodobenzylguanidine Scintigraphic Assessment of Myocardial Sympathetic Innervation in Patients With Familial...  Iodine-123 Metaiodobenzylguanidine Scintigraphic Assessment of Myocardial Sympathetic Innervation in Patients With Familial...
1990) Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 119:1329- ... 1981) Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 22:129-132. ... 1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I] iodobenzylguanidine. J Nucl Med 21: ... an analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation 89:667-683. ...
more infohttp://www.onlinejacc.org/content/29/1/168?ijkey=9a8be767e80a1d5593434dd1d6c9a5b7f270958f&keytype2=tf_ipsecsha
Extraadrenal Pheochromocytoma: I-123 MIBG  Extraadrenal Pheochromocytoma: I-123 MIBG
I-123 MIBG (meta-iodobenzylguanidine). *Patient preparation include: suspend all medications that could interfere with MIBG ...
more infohttp://radiologyinthai.blogspot.com/2010/01/extraadrenal-pheochromocytoma-i-123.html
Pheochromocytoma and Paraganglioma Treatment (PDQ )  Pheochromocytoma and Paraganglioma Treatment (PDQ )
Buscombe JR, Cwikla JB, Caplin ME, et al.: Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in ... 2] [3] Pheochromocytoma is present in 0.1% to 1% of patients with hypertension, [4] [5] [6] and it is present in approximately ... 1] [2] [3] [4] [5] [6] [7]. References: * Plouin PF, Chatellier G, Fofol I, et al.: Tumor recurrence and hypertension ... Nat Genet 42 (3): 229-33, 2010.. * Neumann HP, Pawlu C, Peczkowska M, et al.: Distinct clinical features of paraganglioma ...
more infohttps://www.meb.uni-bonn.de/cancer.gov/CDR0000681246.html
Clinical presentation and diagnosis of pheochromocytoma  Clinical presentation and diagnosis of pheochromocytoma
Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial ... Arch Fam Med 1994; 3:55.. *Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma ... 3]. However, this is likely to be an underestimate as 50 percent of pheochromocytomas were diagnosed at autopsy in one series [ ...
more infohttps://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-pheochromocytoma
Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging - Full Text View - ClinicalTrials.gov  Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging - Full Text View - ClinicalTrials.gov
Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging. The safety and scientific validity of this study ... 3-Iodobenzylguanidine. Anti-Infective Agents, Local. Anti-Infective Agents. Trace Elements. Micronutrients. Growth Substances. ... and 3) by performing a special heart scan. ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01522378
123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis.  123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis.
Received Day: 22 Month: 3 Year: 2012. Accepted Day: 25 Month: 6 Year: 2012. Electronic publication date: Day: 18 Month: 7 Year ... 3). Also, the wash-out rate was significantly higher in these patients (−3.3 ± 9.9 % vs. 17 ± 10 %, p , 0.001; Fig. 4). There ... 3.. Klein AL,Hatle LK,Taliercio CP,Taylor CL,Kyle RA,Bailey KR,et al. Serial Doppler echocardiographic follow-up of left ... Table 3 summarizes the echocardiographic examination results. Left and right ventricular wall thickness was overall normal in ...
more infohttp://www.biomedsearch.com/nih/123I-Labelled-metaiodobenzylguanidine-evaluation-cardiac/22806059.html
Technetium Tc 99m Pyrophosphate
     Summary Report | CureHunter  Technetium Tc 99m Pyrophosphate Summary Report | CureHunter
Phosphoric Acids: 3*Phosphates: 1226*Polyphosphates: 112*Diphosphates: 62*Technetium Tc 99m Pyrophosphate: 172*technetium Tc ... 3. Amyloidosis 07/01/1993 - "[Technetium TC 99m pyrophosphate myocardial scintigraphy in amyloidosis. ". 01/01/1990 - "Soft- ... 99mTc-Pyrophosphate; Diphosphoric Acid, Technetium Salt; Tc-PYP; Technetium Tc 99m Pyrophosphate, Tc(3+) Salt (3:4); Technetium ...
more infohttp://www.curehunter.com/public/keywordSummaryD016698-Technetium-Tc-99m-Pyrophosphate.do
Olivier Rascols Research on Parkinson Disease (Parkinsons Disease)
     | CureHunter  Olivier Rascol's Research on Parkinson Disease (Parkinson's Disease) | CureHunter
3. Antidepressive Agents (Antidepressants)IBA 12/2012 - 06/2010. 3. Dopamine Agents (Dopaminergic Agents)IBA 07/2012 - 01/2006 ... 3/2014. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose ... 3/2014. Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.. ...
more infohttp://www.curehunter.com/public/authorSummary-Rascol,%20Olivier.do?keywordId=D010300
Browsing Scholarly Articles by Affiliation of Duke Author(s) Institutes and Centers  Browsing Scholarly Articles by Affiliation of Duke Author(s) "Institutes and Centers"
An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to ... 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.  ...
more infohttps://dukespace.lib.duke.edu/dspace/handle/10161/2841/browse?type=affiliation&value=Institutes+and+Centers
Browsing Scholarly Articles by Title  Browsing Scholarly Articles by Title
An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to ... 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.  ... 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1ß interferes with ...
more infohttps://dukespace.lib.duke.edu/dspace/handle/10161/2841/browse?type=title
Patent search - Patent Attorneys - Patent Applications - Patent Sale  Patent search - Patent Attorneys - Patent Applications - Patent Sale
I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent , Patient medical information and education container , Ether ... New thieno[2,3-b] pyrrole compounds of the formula: ##STR1## in which: R.sub.1 is hydrogen or lower alkyl, R.sub.2 is cyano, ... I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent. A novel compound, 4-amino-3-iodobenzylguanidine, in ... Antimigraine 8-[3-(4-aminocarbonyl piperazino and piperidino) propyl[xanthines. Xanthine compounds of the formula: ##STR1## in ...
more infohttp://www.patents.com/search?keyword=medicine&page=184
Department of Angiocardiology - Research Output
     - Kyushu University  Department of Angiocardiology - Research Output - Kyushu University
Makaya, M. & Tsutsui, H., Mar 15 2011, In : Respiration and Circulation. 59, 3, p. 267-274 8 p.. Research output: Contribution ... Tsuchihashi-Makaya, M., Matsuo, H., Kakinoki, S., Takechi, S., Kinugawa, S. & Tsutsui, H., Apr 3 2013, In : Circulation Journal ... 3, p. 39-42 4 p.. Research output: Contribution to journal › Article ... 3, p. 197-202 6 p.. Research output: Contribution to journal › Article ...
more infohttps://kyushu-u.pure.elsevier.com/en/organisations/department-of-angiocardiology/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle&page=3
Department of Advanced Medical Initiatives - Research Output
     - Kyushu University  Department of Advanced Medical Initiatives - Research Output - Kyushu University
Ide, T., Jul 1 2015, In : Japanese Journal of Clinical Chemistry. 44, 3, p. 191-197 7 p.. Research output: Contribution to ... Novel, high-definition 3-D endoscopy system with real-time compression communication system to aid diagnoses and treatment ... Establishment of a two-dimensional chiral HPLC system for the simultaneous detection of lactate and 3-hydroxybutyrate ... 3, p. 267-273 7 p.. Research output: Contribution to journal › Article ...
more infohttps://kyushu-u.pure.elsevier.com/en/organisations/department-of-advanced-medical-initiatives/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle&page=5
Qatar Biomedical Research Institute - Research Output
     - Pure: Researcher Portal  Qatar Biomedical Research Institute - Research Output - Pure: Researcher Portal
Effect of pembrolizumab on CD4 + CD25 + , CD4 + LAP + and CD4 + TIM-3 + T cell subsets Toor, M., Nair, V., Pfister, G. & Elkord ... Nair, V., Toor, M., Ali, B. R. & Elkord, E., 3 May 2018, (Accepted/In press) In : Expert Opinion on Therapeutic Targets. p. 1- ... Aigha, I. I., Memon, B., Elsayed, A. K. & Mohamed, E., 3 Apr 2018, In : Stem Cell Research and Therapy. 9, 1, 83.. Research ... Al-Khadairi, G., Naik, A., Thomas, R., Al-Sulaiti, B., Rizly, S. & Decock, J., 3 Jan 2019, In : Journal of Translational ...
more infohttps://qfrd.pure.elsevier.com/en/organisations/qatar-biomedical-research-institute/publications/
Oxytocin supplement vitamin shoppe - Libido For Her Homeopathic Spray (herbal) - Jan 31, 2018  Oxytocin supplement vitamin shoppe - Libido For Her Homeopathic Spray (herbal) - Jan 31, 2018
Buy products such as Spring Valley: Vitamin D-3 Maximum Strength Softgels 5000 Iu Dietary Supplement, 100 ct at Walmart and ... Donna, Daddy's Naughty Daughter(to Ch.3) - Writing.Com (little girl touches teachers penis). Twitter.com/cemproducts Sale!!! - ... Just spray it under your tongue up to 3 times a day to help promote sexual vitality. ... www.longecity.org/forum/topic/51732-chemical ly-induced-ltp/page-3) That would slow the break down of oxytocin... This person ...
more infohttp://libidoforher.herbalyzer.com/oxytocin-supplement-vitamin-shoppe.html
  • The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan. (clinicaltrials.gov)
  • De geidentificeerde knelpunten zijn omgezet in 16 voorwaarden voor optimale netwerkzorg bij de ZvP, die genummerd zijn weergegeven in een model voor optimale netwerkzorg ( aanverwant product: model organisatie netwerkzorg parkinson ) en zijn uitgeschreven in een visgraatdiagram ( aanverwant product: Voorwaarden optimale organisatie netwerkzorg Parkinson ). (richtlijnendatabase.nl)